Go to content
UR Home

Non-Invasive Prediction of IDH Mutation in Patients with Glioma WHO II/III/IV Based on F-18-FET PET-Guided In Vivo 1H-Magnetic Resonance Spectroscopy and Machine Learning

URN to cite this document:
DOI to cite this document:
Bumes, Elisabeth ; Wirtz, Fro-Philip ; Fellner, Claudia ; Grosse, Jirka ; Hellwig, Dirk ; Oefner, Peter J. ; Häckl, Martina ; Linker, Ralf A. ; Proescholdt, Martin A. ; Schmidt, Nils Ole ; Riemenschneider, Markus J. ; Samol, Claudia ; Rosengarth, Katharina ; Wendl, Christina M. ; Hau, Peter ; Gronwald, Wolfram ; Hutterer, Markus
License: Creative Commons Attribution 4.0
PDF - Published Version
Date of publication of this fulltext: 27 Nov 2020 13:09


Simple Summary Approximately 75-80% of according to the classification of world health organization (WHO) grade II and III gliomas are characterized by a mutation of the isocitrate dehydrogenase (IDH) enzymes, which are very important in glioma cell metabolism. Patients with IDH mutated glioma have a significantly better prognosis than patients with IDH wildtype status, typically seen in ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: datahub@ur.de
0941 943 -5707

Contact persons